There is a link between erectile dysfunction and heart failure: it could be inflammation.

Abstract:

:The rates of erectile dysfunction (ED) in heart failure (HF) are extremely high. Limited capacity of patients with HF to exercise and coronary artery disease are considered to be the main causative mechanisms. Both HF and ED are associated with increased levels of proinflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) and interleukin-8 (IL- 8). The increased levels of proinflammatory cytokines in ED suggest that inflammatory markers act as important active agents in ED development. The innate immune system also reacts to danger signals released by damaged cells. Damage-associated molecular patterns (DAMPs) are molecules released as a result of tissue injury acting on immune activation during non-infectious inflammation. DAMPs may also reach the circulation and mediate pathophysiological processes that occur in distant organs to the injured site. Cardiomyocytes possess abundant mitochondria and during tissue damage, it is likely that the heart releases high amounts of mitochondrial DNA (mtDNA), which acts as a potent ligand for Toll-like receptor 9 (TLR9). Accordingly, in the present manuscript we review the literature pertaining the relationship between HF and ED and the subjacent inflammatory process associated to both diseases. In addition, we propose the hypothesis that TLR9 activation by DAMPs released in HF leads to inflammation, vascular dysfunction and functional changes in cavernosal tissue, providing an additional mechanism that connects HF to ED. Since TNF-α usually is a product of TLRs activation and seems to be a common link between HF and ED, our hypothesis provide two possible targets to treat the ED associated to HF and may have important preventative and therapeutic implications.

journal_name

Curr Drug Targets

journal_title

Current drug targets

authors

Rodrigues FL,Fais RS,Tostes RC,Carneiro FS

doi

10.2174/1389450116666150420145757

subject

Has Abstract

pub_date

2015-01-01 00:00:00

pages

442-50

issue

5

eissn

1389-4501

issn

1873-5592

pii

CDT-EPUB-66668

journal_volume

16

pub_type

杂志文章,评审
  • The Molecular Concept of Atheromatous Plaques.

    abstract:BACKGROUND:Recently, there are scientific attempts to discover new drugs in the biotechnology industry in order to treat various diseases including atherosclerosis. OBJECTIVE:The main objective of the present review was to highlight the cellular, molecular biology and inflammatory process related to the atheromatous p...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450117666160502151600

    authors: Thent ZC,Chakraborty C,Mahakkanukrauh P,Nik Ritza Kosai Nik Mahmood N,Rajan R,Das S

    更新日期:2017-01-01 00:00:00

  • Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay.

    abstract::The use of imatinib, second and third generation ABL tyrosine kinase inhibitors (TKI) (i.e. dasatinib, nilotinib, bosutinib and ponatinib) made CML a clinically manageable and, in a small percentage of cases, a cured disease. TKI therapy also turned CML blastic transformation into a rare event; however, disease progre...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450117666160615074120

    authors: Perrotti D,Silvestri G,Stramucci L,Yu J,Trotta R

    更新日期:2017-01-01 00:00:00

  • PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future Perspectives.

    abstract::Five programmed death-1/programmed death-ligand 1 (PD-L1) inhibitors are currently approved for the treatment of locally advanced or metastatic urothelial carcinoma of the bladder and the upper urinary tract. Following the FDA and EMA restrictions of first-line treatment with Atezolizumab and Pembrolizumab in platinum...

    journal_title:Current drug targets

    pub_type: 杂志文章

    doi:10.2174/1389450121666200510015216

    authors: Gevaert T,Cimadamore A,Montironi R,Eckstein M

    更新日期:2020-05-09 00:00:00

  • Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels.

    abstract::Currently, low density lipoprotein cholesterol (LDL-C) levels are the main, if not the only, lipid target in the effort to reduce cardiovascular disease (CVD) morbidity and mortality. Several primary and secondary CVD prevention trials with statins shaped current guidelines and provided detailed targets across a range...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/138945007780058933

    authors: Athyros VG,Mikhailidis DP,Kakafika AI,Karagiannis A,Hatzitolios A,Tziomalos K,Ganotakis ES,Liberopoulos EN,Elisaf M

    更新日期:2007-03-01 00:00:00

  • Progress in the Understanding of the Immune Microenvironment and Immunotherapy in Malignant Pleural Mesothelioma.

    abstract::Malignant pleural mesothelioma (MPM) is a remarkably aggressive thoracic malignancy with a limited survival of only 5-12 months. However, MPM still remains unresponsive to conventional standards of treatment, including pleurectomy and decortication, extrapleural pneumonectomy for resectable disease with or without che...

    journal_title:Current drug targets

    pub_type: 杂志文章

    doi:10.2174/1389450121666200719011234

    authors: Cheng L,Li N,Xu XL,Mao WM

    更新日期:2020-01-01 00:00:00

  • Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology.

    abstract:BACKGROUND:The Coronavirus Disease 2019 (COVID-19) is becoming the major health issue in recent human history with thousands of deaths and millions of cases worldwide. Newer research and old experience with other corona-viruses highlighted a probable underlying mechanism of disturbance of the renin-angiotensin system (...

    journal_title:Current drug targets

    pub_type: 杂志文章

    doi:10.2174/1389450121666201020154033

    authors: Vieira C,Nery L,Martins L,Jabour L,Dias R,Simões E Silva AC

    更新日期:2020-10-20 00:00:00

  • Tachykinins: role in human gastrointestinal tract physiology and pathology.

    abstract::Tachykinins (TKs) and their receptors (NK1, NK2 and NK3), which are diffusely expressed in the human gastrointestinal tract, represent an endogenous modulator system regulating enteric secretomotor functions, inflammatory and immune responses, and visceral hypersensitivity, mainly during pathological gut diseases. Pat...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/138945006778019354

    authors: Improta G,Broccardo M

    更新日期:2006-08-01 00:00:00

  • Prediction of Late Recurrence and Distant Metastasis in Early-stage Breast Cancer: Overview of Current and Emerging Biomarkers.

    abstract::Recently, a significant number of breast cancer (BC) patients have been diagnosed at an early stage. It is therefore critical to accurately predict the risk of recurrence and distant metastasis for better management of BC in this setting. Clinicopathologic patterns, particularly lymph node status, tumor size, and horm...

    journal_title:Current drug targets

    pub_type: 杂志文章

    doi:10.2174/1389450121666200312105908

    authors: Gouri A,Benarba B,Dekaken A,Aoures H,Benharkat S

    更新日期:2020-01-01 00:00:00

  • Recent advances in the discovery of metallo-β-lactamase inhibitors for β-lactam antibiotic-resistant reversing agents.

    abstract::The overuse of antibiotics which exerts the selective pressure for bacterial pathogens has facilitated the spread of antibiotics' resistance. Metallo-β-lactamases (MβLs) are zinc enzymes produced by an increasing number of bacterial pathogens. They can readily cleave carbapenems and most other β-lactams that are mains...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450115666140326094504

    authors: Guo Z,Ma S

    更新日期:2014-01-01 00:00:00

  • Is surfactant a promising additive drug in ALI/ARDS-patients?

    abstract::The rationale for surfactant replacement therapy in patients with acute respiratory distress syndrome (ARDS) is to restore the normal composition of the surfactant system, as well as to overcome ongoing inactivation of present surfactant. Indeed, surfactant replacement therapy can normalize the composition of the surf...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450043345399

    authors: Schultz MJ,Kesecioglu J

    更新日期:2004-07-01 00:00:00

  • Targeting c-MET/HGF signaling pathway in upper gastrointestinal cancers: rationale and progress.

    abstract::Aberrant activation of receptor-tyrosine kinase c-Met/HGF pathway is shown to be associated with cell proliferation, invasion, metastasis and poor-prognosis in several tumor types, including upper gastrointestinal-malignancies. The interaction of c-Met with multiple signalling-pathways involved in tumorigenic-properti...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450115666141107105456

    authors: Gholamin S,Fiuji H,Maftouh M,Mirhafez R,Shandiz FH,Avan A

    更新日期:2014-01-01 00:00:00

  • Multidrug transporters as drug targets.

    abstract::Transport molecules can significantly affect the pharmacodynamics and pharmacokinetics of drugs. An important transport molecule, the 170 kDa P-glycoprotein (Pgp), is constitutively expressed at several organ sites in the human body. Pgp is expressed at the blood-brain barrier, in the kidneys, liver, intestines and in...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/138945006778019264

    authors: Liang XJ,Aszalos A

    更新日期:2006-08-01 00:00:00

  • Targeting PPAR isoforms following CNS injury.

    abstract::A major focus has developed for the discovery of proregenerative and neuroprotective therapeutic agents to help the millions of Americans who receive a CNS injury annually. Tribulations have been encountered along the way due to the complicated set of pathways that are initiated post-injury. To target this complicated...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450111314070003

    authors: Yonutas HM,Sullivan PG

    更新日期:2013-06-01 00:00:00

  • Prospectives of Antihypertensive Nano-ceuticals as Alternative Therapeutics.

    abstract:BACKGROUND:Global death rate due to cardiovascular diseases (CVDs) is highest as compared to other ailments. Principal risk factor associated with CVDs is hypertension. Major classes of current antihypertensive (AHT) therapies include angiotensin converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARBs)...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450117666160711163119

    authors: Niaz T,Hafeez Z,Imran M

    更新日期:2017-01-01 00:00:00

  • The link between Hepatic Vitamin A Metabolism and Nonalcoholic Fatty Liver Disease.

    abstract::The liver is essential for the control of glucose and lipid metabolism. Excessive accumulation of fat in the liver disturbs its function and leads to the development of fatty liver diseases. The nonalcoholic fatty liver disease (NAFLD) is a common type of fatty liver disease found in patients who have not consumed sig...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450116666150325231015

    authors: Chen G

    更新日期:2015-01-01 00:00:00

  • Is Intake of Flavonoid-Based Food Supplements During Pregnancy Safe for the Developing Child? A Literature Review.

    abstract::Due to potential health benefits and the general assumption that natural products are safe, there is an increasing trend in the general population - including pregnant women - to supplement their diet with flavonoid-based food supplements. In addition, preclinical studies aim to prevent developmental adverse effects i...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450116666150804110049

    authors: Barenys M,Masjosthusmann S,Fritsche E

    更新日期:2017-01-01 00:00:00

  • Targeting Autophagic Pathways by Plant Natural Compounds in Cancer Treatment.

    abstract::Nowadays, natural compounds of plant origin with anticancer effects have gained more attention because of their clinical safety and broad efficacy profiles. Autophagy is a multistep lysosomal degradation pathway that may have a unique potential for clinical benefit in the setting of cancer treatment. To retrieve artic...

    journal_title:Current drug targets

    pub_type: 杂志文章

    doi:10.2174/1389450121666200504072635

    authors: Forouzanfar F,Mousavi SH

    更新日期:2020-01-01 00:00:00

  • Accuracy of 25-hydroxyvitamin D assays: confronting the issues.

    abstract::Measurement of 25-hydroxyvitamin D (25-OHD) is widely used for assessing vitamin D status. There has been a dramatic increase in 25-OHD requests over recent years prompting many laboratories to consider the use of automated immunoassays. To achieve higher throughput, these methods have abandoned the traditional solven...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/138945011793591608

    authors: Carter GD

    更新日期:2011-01-01 00:00:00

  • EGFR Transactivation by Peptide G Protein-Coupled Receptors in Cancer.

    abstract::Lung cancer kills approximately 1.3 million citizens in the world annually. The tyrosine kinase inhibitors (TKI) erlotinib and gefitinib are effective anti-tumor agents especially in lung cancer patients with epidermal growth factor receptor (EGFR) mutations. The goal is to increase the potency of TKI in lung cancer p...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450116666150107153609

    authors: Moody TW,Nuche-Berenguer B,Nakamura T,Jensen RT

    更新日期:2016-01-01 00:00:00

  • Structure, pharmacology and therapeutic prospects of family C G-protein coupled receptors.

    abstract::Family C of G-protein coupled receptors (GPCRs) from humans is constituted by eight metabotropic glutamate (mGlu(1-8)) receptors, two heterodimeric gamma-aminobutyric acid(B) (GABA(B)) receptors, a calcium-sensing receptor (CaR), three taste (T1R) receptors, a promiscuous L-alpha-amino acid receptor (GPRC6A), and five...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/138945007779315614

    authors: Bräuner-Osborne H,Wellendorph P,Jensen AA

    更新日期:2007-01-01 00:00:00

  • Hepatitis C virus proteins as targets for drug development: the role of bioinformatics and modelling.

    abstract::Hepatitis C virus (HCV), a member of the Flaviviridae family, has been recognised to be responsible for both parenterally transmitted and sporadic non-A and non-B hepatitis affecting 1-3% of the world population. HCV is a positive stranded RNA virus encoding a single polyprotein which contains at least ten unique stru...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450023347650

    authors: Lahm A,Yagnik A,Tramontano A,Koch U

    更新日期:2002-08-01 00:00:00

  • Antiphospholipid syndrome: characteristics and obstetrical management.

    abstract::Antiphospholipid syndrome (APS) is characterized by a combination of clinical features consisted of thrombotic or pregnancy-related events and autoimmune antiphospholipid antibodies. In the 1998 International Consensus Preliminary Criteria, APS is defined by the concomitant presence of these clinical features and labo...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450054545999

    authors: Nishiguchi T,Kobayashi T

    更新日期:2005-08-01 00:00:00

  • New Compounds Targeting the Androgen Receptor for Treatment of Advanced Prostate Cancer.

    abstract::The androgen receptor (AR) signalling pathway remains a key driver of prostate cancer progression despite castrate levels of testosterone in advanced disease. The androgen biosynthesis inhibitor abiraterone and the anti-androgen enzalutamide have been shown to prolong survival in randomized clinical trials both pre-an...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450116666150907101044

    authors: Assi R,Temraz S,Shamseddine A,Mukherji D

    更新日期:2016-01-01 00:00:00

  • Vascular disrupting agents (VDA) in oncology: advancing towards new therapeutic paradigms in the clinic.

    abstract::Vascular Disrupting Agents (VDA) are a potential new class of oncology drugs that have garnered attention recently as a number of these agents have entered into Phase 2-3 studies. Currently available data suggest how the subsequent evolution of these agents into clinical practice may proceed, with new therapeutic para...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/138945011798829366

    authors: Spear MA,LoRusso P,Mita A,Mita M

    更新日期:2011-12-01 00:00:00

  • Targeting the RAS signaling pathway in malignant hematologic diseases.

    abstract::Molecularly targeting signaling pathways that are involved in the pathogenesis of hematopoietic malignancies may lead to more specific and efficacious therapies. Activation of the RAS signal transduction cascade is a common feature in the molecular pathogenesis of hematologic malignancies. A number of novel agents tar...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/138945007779940043

    authors: Morgan MA,Ganser A,Reuter CW

    更新日期:2007-02-01 00:00:00

  • Potential Enzymatic Targets in Alzheimer's: A Comprehensive Review.

    abstract::Alzheimer's, a degenerative cause of the brain cells, is called as a progressive neurodegenerative disease and appears to have a heterogeneous etiology with main emphasis on amyloid-cascade and hyperphosphorylated tau-cascade hypotheses, that are directly linked with macromolecules called enzymes such as β- & γ-secret...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450119666180820104723

    authors: Alam J,Sharma L

    更新日期:2019-01-01 00:00:00

  • The Therapeutic Potential of Quercetin in Parkinson's Disease: Insights into its Molecular and Cellular Regulation.

    abstract::Parkinson's disease (PD) is a chronic and progressive neurodegenerative disorder characterized by the progressive death of dopaminergic neurons in the substantia nigra pars compacta (SNc). PD is a multifactorial disorder, with several different factors being suggested to play a synergistic pathophysiological role, inc...

    journal_title:Current drug targets

    pub_type: 杂志文章

    doi:10.2174/1389450120666191112155654

    authors: Tamtaji OR,Hadinezhad T,Fallah M,Shahmirzadi AR,Taghizadeh M,Behnam M,Asemi Z

    更新日期:2020-01-01 00:00:00

  • Improving the embryo implantation via novel molecular targets.

    abstract::With the development of modern assisted reproductive technology(ART), the treatment of infertility and the pregnant outcome by ART have been significantly improved. However, implantation failure, particularly the unexplained repeated implantation failure (RIF), is still the unsolved and principal problem to affect the...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450111314080006

    authors: Li J,Liang X,Chen Z

    更新日期:2013-07-01 00:00:00

  • Proline Oxidase (POX) as A Target for Cancer Therapy.

    abstract::Proline dehydrogenase/proline oxidase (PRODH/POX) is an enzyme catalyzing the first step of proline degradation, during which ROS and/or ATP is generated. POX is widely distributed in living organisms and is responsible for a number of regulatory processes such as redox homeostasis, osmotic adaptation, cell signaling ...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/138945011613151031150637

    authors: Kononczuk J,Czyzewska U,Moczydlowska J,Surażyński A,Palka J,Miltyk W

    更新日期:2015-01-01 00:00:00

  • Endogenous Cardioprotective Agents: Role in Pre and Postconditioning.

    abstract::Cardiovascular diseases (CVD) are the leading cause of death, chronic illness and disability in Western countries. The most common cause of CVD derives from the harmful effects of acute myocardial ischemia and subsequent reperfusion injury. Cardioprotection against acute ischemia/ reperfusion injury is made possible b...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450116666150309115536

    authors: Penna C,Granata R,Tocchetti CG,Gallo MP,Alloatti G,Pagliaro P

    更新日期:2015-01-01 00:00:00